BLUE EARTH DIAGNOSTICS BOARD


Our Directors come from a wide-range of relevant backgrounds and make an active contribution to company strategy.


Board OF DIRECTORS

Fulvio Renoldi Bracco
Chief Executive Officer at Bracco Imaging
Fulvio Renoldi Bracco

Fulvio Renoldi Bracco holds a degree in Economics from “Bocconi” University in Milan where he graduated with a final dissertation based on US and EU regulations on Mergers and Acquisitions.

He subsequently spent four years in Citibank in London, New York and Milan where he finally specialized in structured finance products for the financial institution industry.

Since 1996, he joined his family in the management of Bracco S.p.A., where he initially worked in the corporate Finance Department.

In 2002 he became Chairman and CEO of Acist, a US Affiliate of the Bracco Group, specialized in the development manufacturing and marketing of proprietary cutting edge medical systems.

In April 2009 he became the head of the Global Business Unit Imaging of Bracco Imaging S.p.A., one of the World’s leading companies in the diagnostic imaging business. Part of Bracco S.p.A., the holding company of Bracco Group, Bracco Imaging operates in over 90 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, license and distribution partnership agreements.

In June 2017 he was appointed Chief Executive Officer of Bracco Imaging S.p.A.

He is a member of the Presidential Committee of Federchimica, – the Italian Federation of the chemical industry – of the BoD of the American Chamber of Commerce in Italy and of the BoD of Endeavor Italy.

In addition he is member of the BoD of Bracco S.p.A. and Centro Diagnostico Italiano.

He is married with two sons

MarcoCampione_535x400px WEBSITE
President and Chief Executive Officer at Blue Earth Diagnostics
Marco Campione

Marco leads Blue Earth Diagnostics, an established global molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer.  Blue Earth Diagnostics’ clinical focus is exclusively on cancer, with an expanding pipeline in disease states. Blue Earth Diagnostics’ strategy is to apply its knowledge and expertise to developing promising cancer radiopharmaceuticals for imaging.

Marco brings more than 25 years of industry experience to his role as President & Chief Executive Officer.  He lived and worked in multiple countries around the world.  Prior to joining Blue Earth Diagnostics from GE HealthCare, he served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc.

He was responsible for the Pharmaceutical Diagnostics business unit in North America, with oversight for its strategy, management and overall commercial operations throughout the United States and Canada.

Amongst other top management roles at GE HealthCare, Marco served as President and CEO of Southern Europe.  He also served as President of the Italian Medical Device Industry Association with Confindustria.

Before joining GE HealthCare, Marco worked at FiatAvio as integrated logistic support leader for military engines and beforehand served the Italian Military an Anti-aircraft Artillery Technical Control Officer.

He is a Board Member of the Massachusetts Prostate Cancer Coalition, and a Committee Member of the Richi Childhood Cancer Foundation.

Born in Milan, Italy, Marco holds both Italian and Swiss citizenships.  He is an Engineering graduate of the Polytechnic of Turin (BE, ME), and received his MBA from University of Turin, and La Sorbonne, Paris.

Marco lives in the Greater Boston area with his wife Rossella and their son Francesco. Off the clock, he enjoys reading, travelling, and playing tennis.

image
Chief Financial Officer at Bracco Imaging
Roberto Desimini

Roberto Desimini began his career in 1983 at Arthur Andersen in Milan as an auditor.

In 1988 he joined the San Raffaele Hospital in Milan, as assistant to the General Manager and in charge of administration and accounting of some subsidiaries.

In 1990 he began his experience in Bracco S.p.A., coinciding with the start of the company internationalization process, as head of Consolidated Financial Statements. In 2007 he was appointed Director with the Corporate role of Chief Financial Officer, a position that he still holds.

Cyrille Petit
Chief Corporate Development Officer and Head of Strategic Initiatives at Bracco Imaging
Cyrille Petit

Cyrille joined Bracco S.p.A. in 2019 as Chief Corporate Development Officer and Head of Strategic Initiatives.

He started his career in investment banking, at Goldman Sachs in London then joined General Electric, where he had a 15-year tenure holding various position in Global Business Development. He left to join the executive committee of Smith & Nephew plc, as Chief Corporate Development Officer and Head of Global Business Services.

Cyrille has a strong track-record in strategy, M&A, building global support functions, running integration, cost reduction programs, and advising boards.

Cyrille is married with 5 sons and enjoys sailing, running and skiing. He holds a Masters in Finance from HEC Paris.

Fabio Tedoldi
Director of R&D of the Global Business Unit Imaging of Bracco
Fabio Tedoldi

Fabio holds a Ph.D in Physics from the University of Pavia. His thesis on low-dimensional quantum magnetism continued to be the focus for the following two years as part of his Post-Doctoral Research.

Fabio started his career at Bruker as an Application Specialist and Project Leader, moving to Bracco Imaging S.p.A. in 2008. Starting as Preclinical Imaging Department Manager in the R&D Centre based in Ivrea, he subsequently held the position of Director of the same Centre and today the role of Director of R&D of the Global Business Unit Imaging of Bracco.

Fabio is also Managing Director of SurgVision GmBH, member of the Board of Directors of Blue Earth Diagnostics and Blue Earth Therapeutics, as well as of the Gruppo Tecnico Ricerca e Sviluppo of Confindustria and of the Gruppo Tecnico Università e Ricerca of Assolombarda.

His scientific CV includes approximately 45 peer reviewed papers and 10 patents.

 

UKBED-N/A-2500008 / March 2025